Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

More than 2,500 patients are currently waiting for that lifesaving transplant in Michigan. More than 100,000 are waiting ...

Risk factors for the development of interstitial lung disease following severe COVID ... Short-Form 6-Dimension and King's Sarcoidosis Questionnaire in people with sarcoidosis associated fatigue.

The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ...

However, pulmonary manifestations and symmetric oligoarthritis ... the most likely autoimmune disorder in this case is sarcoidosis. This multisystem granulomatous disorder can involve any organ ...

Sarcoidosis is a rare systemic disease that afflicts an estimated 200,000 people in the U.S., more often people who are Black ...

Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...

The Foundation for Sarcoidosis Research (FSR) has awarded three pilot grants in the amount of $100,000 each, to Dr. Satish Sati from the ...

Dearring was diagnosed in 2010 with sarcoidosis — a chronic disease that caused debilitating lesions in her lungs. Her doctor’s news was shocking: She couldn’t leave the hospital until she ...